Lupin Limited and Mylan Pharmaceuticals Inc. have collaborated to launch Lupin’s biosimilar Nepexto (etanercept) in the German market. The partnership to bring Nepexto to Germany was announced shortly after the biosimilar was approved by the European Medicines Agency.
Thierry Volle, president for EMEA at Lupin, said, “Nepexto is our first biosimilar to receive regulatory approval in Europe.” He...






